Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1138-1144

  Ejlertsen, B ^a   Aldridge, J ^b   Nielsen, K V ^c   Regan, M M ^b,d   Henriksen, K L ^e   Lykkesfeldt, A E ^e   Muller S ^c   Gelber, R D ^b,d,f   Price, K N ^b,f   Rasmussen, B B ^g   Viale, G ^h   Mouridsen, H ^a  

^a Rigshospitalet   (Denmark)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c AGILENT TECHNOLOGIES   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Aromatase inhibitor; Breast cancer; ERBB2; ESR1; HER2; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; EARLY CANCER; ESTROGEN RECEPTOR 1 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENETIC HETEROGENEITY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; ONCOGENE; PATIENT ASSESSMENT; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL;

EID: 84860462662     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr438     Document Type: Article

References (28)

1. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472): 1687-1717.
2. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20(8): 1319-1329.
3. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28(16): 2784-2795.
4. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
5. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7(7): 545-553.
6. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10(4): R65.
7. Lehr HA, Hansen DA, Kussick S et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol 1999; 30(11): 1314-1320.
8. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999; 17(2): 470-477.
9. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101(10): 736-750.
10. Holst F, Stahl PR, Ruiz C et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007; 39(5): 655-660.
11. Nielsen KV, Ejlertsen B, Muller S et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 2011; 127(2): 345-355.
12. Tomita S, Zhang Z, Nakano M et al. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 2009; 100(6): 1012-1017.
13. BIG 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353(26): 2747-2757.
14. BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361(8): 766-776.
15. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25(25): 3846-3852.
16. Rasmussen BB, Regan MM, Lykkesfeldt AE et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9(1): 23-28.
17. Viale G, Giobbie-Hurder A, Regan MM et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26(34): 5569-5575.
18. Henriksen KL, Rasmussen BB, Lykkesfeldt AE et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007; 60(4): 397-404.
19. Colleoni M, Giobbie-Hurder A, Regan MM et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29: 1117-1124.
20. Adelaide J, Finetti P, Charafe-Jauffret E et al. Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 2008; 123(12): 2970-2972.
21. Horlings HM, Bergamaschi A, Nordgard SH et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008; 40(7): 807-808.
22. Brown LA, Hoog J, Chin SF et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008; 40(7): 806-807.
23. Vincent-Salomon A, Raynal V, Lucchesi C et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008; 40(7): 810-812.
24. Reis-Filho JS, Drury S, Lambros MB et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008; 40(7): 809-810.
25. Moelans CB, Monsuur HN, de Pinth JH et al. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cell Oncol (Dordr) 2011; doi: 10.1007/s13402-011-0045-5.
26. Albertson DG. Conflicting evidence on the frequency of ESR1 amplification in breast cancer. Nat Genet 2008; 40(7): 821-822.
27. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177-182.
28. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008; 26(7): 1059-1065.